[Vendor] BCH vs KP on the same compound, same month — both cleared 98.5%
Result first, context after: BCH vs KP on the same compound, same month — both cleared 98.5%. Everything below is how it was ordered, stored and sent.
Figures up front so nobody has to dig: 98.5%.
Read the phase 2 hepatic paper properly and the endpoint definitions were more interesting than the headline response rate.
Independent purity results for this compound are very sparse across the whole site, which means any impression about consistency is built on almost nothing.
Would rather be corrected in public than confident in private.
- KPKP source pageZhuhai Kerui Biotechnology Co., Ltd. · Zhuhai · 94% here, rank 10 · shop at keruipeptides.com →
- BCBCH source pageBachem Holding (Suzhou) Co., Ltd. · Suzhou · 89% here, rank 19 · shop at bachemholding.com →
nofollow and sponsored; nobody here is paid for it.best — the order this archive was captured in
It is a dual agonist at the GLP-1 and glucagon receptors. The glucagon arm is associated with increased energy expenditure and with effects on hepatic fat, which is why the development programme is oriented towards liver disease.
glucagon agonism and energy expenditure is the mechanistic thread
Same. Very thin independent data on this one, which should make everybody here more tentative than they are.
glucagon agonism and energy expenditure is the mechanistic thread
Adding the standing caveat — unapproved compound, research material is not for human use.
Adding the standing caveat — unapproved compound, research material is not for human use.
This is the framing the board needs. It is a hepatic programme first.
That figure is from the obesity programme, and this thread is about the hepatic one.
Asked here what the difference was between the imaging and biopsy endpoints and got a genuinely excellent answer.
the hepatic data is what makes this compound different from the others
Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use.
the titration in the trials was slow and deliberate
Not convinced. Imaging-based fat fraction is not the same as a histological response and the paper is explicit about that.
Left up. It reads the paper carefully and is explicit about the population.
Agreed. The hepatic programme is the point of this compound and the weight discussion is a side effect of the side effect.
- 1glucagon agonism and energy expenditure is the mechanistic thread6 comments in this branch · started by u/peak_area_pete